Literature DB >> 22001777

Transcriptional and posttranslational inhibition of dioxin-mediated induction of CYP1A1 by harmine and harmol.

Mohamed A M El Gendy1, Anatoly A Soshilov, Michael S Denison, Ayman O S El-Kadi.   

Abstract

Dioxins are widespread environmental contaminants that induce the carcinogen-activating enzyme, cytochrome P450 1A1 (CYP1A1) through an aryl hydrocarbon receptor (AhR)-dependent mechanism. We previously demonstrated that harmine inhibits the dioxin-mediated induction of Cyp1a1 activity in murine hepatoma cells. Therefore, the aim of this study is to determine the effect of harmine and its main metabolite, harmol, on the dioxin-mediated induction of CYP1A1 in human HepG2 and murine Hepa 1c1c7 hepatoma cells. Our results showed that harmine and harmol significantly inhibited the dioxin-mediated induction of CYP1A1 at mRNA, protein, and activity levels in a concentration-dependent manner in human and murine hepatoma cells. Moreover, harmine and harmol inhibited the AhR-dependent luciferase activity and the activation and transformation of AhR using the electrophoretic mobility shift assay. In addition, harmine and harmol displaced [(3)H]TCDD in the competitive ligand binding assay. At posttranslational level, both harmine and harmol decreased the protein stability of CYP1A1, suggesting that posttranslational mechanism is involved. Furthermore, we demonstrated that the underlying mechanisms of the posttranslational modifications of both compounds involve ubiquitin-proteasomal pathway and direct inhibitory effects of CYP1A1 enzyme. We concluded that harmine and its metabolite, harmol, are new inhibitors of dioxin-mediated effects.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22001777      PMCID: PMC3263333          DOI: 10.1016/j.toxlet.2011.09.030

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  39 in total

1.  Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine.

Authors:  Yongcheng Song; Djohan Kesuma; Jian Wang; Yu Deng; Jinao Duan; Jerry H Wang; Robert Z Qi
Journal:  Biochem Biophys Res Commun       Date:  2004-04-23       Impact factor: 3.575

2.  CYP1A1, cigarette smoking, and colon and rectal cancer.

Authors:  Martha L Slattery; W Samowtiz; K Ma; M Murtaugh; C Sweeney; T R Levin; S Neuhausen
Journal:  Am J Epidemiol       Date:  2004-11-01       Impact factor: 4.897

3.  Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine.

Authors:  Ai-Ming Yu; Jeffrey R Idle; Kristopher W Krausz; Adrian Küpfer; Frank J Gonzalez
Journal:  J Pharmacol Exp Ther       Date:  2003-04       Impact factor: 4.030

4.  3'-methoxy-4'-nitroflavone, a reported aryl hydrocarbon receptor antagonist, enhances Cyp1a1 transcription by a dioxin responsive element-dependent mechanism.

Authors:  Junguo Zhou; Thomas A Gasiewicz
Journal:  Arch Biochem Biophys       Date:  2003-08-01       Impact factor: 4.013

Review 5.  Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1.

Authors:  Tsutomu Shimada; Yoshiaki Fujii-Kuriyama
Journal:  Cancer Sci       Date:  2004-01       Impact factor: 6.716

6.  Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a]pyrene.

Authors:  Ariel Revel; Hila Raanani; Edward Younglai; Jing Xu; Ian Rogers; Robin Han; Jean-Francois Savouret; Robert F Casper
Journal:  J Appl Toxicol       Date:  2003 Jul-Aug       Impact factor: 3.446

7.  In vitro activity of the beta-carboline alkaloids harmane, harmine, and harmaline toward parasites of the species Leishmania infantum.

Authors:  C Di Giorgio; F Delmas; E Ollivier; R Elias; G Balansard; P Timon-David
Journal:  Exp Parasitol       Date:  2004 Mar-Apr       Impact factor: 2.011

Review 8.  Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals.

Authors:  Michael S Denison; Scott R Nagy
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002-01-10       Impact factor: 13.820

Review 9.  Ligand binding and activation of the Ah receptor.

Authors:  Michael S Denison; Alessandro Pandini; Scott R Nagy; Enoch P Baldwin; Laura Bonati
Journal:  Chem Biol Interact       Date:  2002-09-20       Impact factor: 5.192

10.  Flavonoids as aryl hydrocarbon receptor agonists/antagonists: effects of structure and cell context.

Authors:  Shu Zhang; Chunhua Qin; Stephen H Safe
Journal:  Environ Health Perspect       Date:  2003-12       Impact factor: 9.031

View more
  5 in total

1.  A network model for angiogenesis in ovarian cancer.

Authors:  Kimberly Glass; John Quackenbush; Dimitrios Spentzos; Benjamin Haibe-Kains; Guo-Cheng Yuan
Journal:  BMC Bioinformatics       Date:  2015-04-11       Impact factor: 3.169

Review 2.  Regulation of Human Cytochrome P4501A1 (hCYP1A1): A Plausible Target for Chemoprevention?

Authors:  Rebeca Santes-Palacios; Diego Ornelas-Ayala; Noel Cabañas; Ana Marroquín-Pérez; Alexis Hernández-Magaña; Sitlali Del Rosario Olguín-Reyes; Rafael Camacho-Carranza; Jesús Javier Espinosa-Aguirre
Journal:  Biomed Res Int       Date:  2016-12-26       Impact factor: 3.411

3.  Harmine and harmaline downregulate TCDD-induced Cyp1a1 in the livers and lungs of C57BL/6 mice.

Authors:  Mohamed A M El Gendy; Ayman O S El-Kadi
Journal:  Biomed Res Int       Date:  2012-12-20       Impact factor: 3.411

4.  Camel milk modulates the expression of aryl hydrocarbon receptor-regulated genes, Cyp1a1, Nqo1, and Gsta1, in murine hepatoma Hepa 1c1c7 cells.

Authors:  Hesham M Korashy; Mohamed A M El Gendy; Abdulqader A Alhaider; Ayman O El-Kadi
Journal:  J Biomed Biotechnol       Date:  2012-02-27

Review 5.  Aryl hydrocarbon receptor antagonism and its role in rheumatoid arthritis.

Authors:  Nam Trung Nguyen; Taisuke Nakahama; Chi Hung Nguyen; Trang Thu Tran; Van Son Le; Hoang Ha Chu; Tadamitsu Kishimoto
Journal:  J Exp Pharmacol       Date:  2015-12-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.